TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.

Edgar T Overton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.